R05DA04 codeine
RESPIRATORY SYSTEM ›COUGH AND COLD PREPARATIONS ›COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS ›Opium alkaloids and derivatives
健保收載品項 TFDA 在效許可證 7 FDA 已核准 健保給付條款 1
台灣藥品與外觀
健保收載品名：磷酸可待因注射液１５毫克/毫升、磷酸可待因錠15毫克、磷酸可待因錠30毫克
無外觀照
可待因磷酸鹽半水合物
無外觀照
"賽諾菲" 磷酸可待因
無外觀照
磷酸可待因
資料來源：食藥署「西藥許可證」＋「藥品 ATC 碼」＋「藥品外觀」＋「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 鎮咳藥、麻醉性鎮痛藥。
- 鎮咳、鎮痛劑。
- 鎮咳、鎮痛。
美國 FDA 適應症（英文原文對照）
1 INDICATIONS AND USAGE Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions ( 5.1 )] , reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsule is a combination product of butalbital, a barbiturate; acetaminophen; caffeine, a methylxanthine; and codeine phosphate, an opioid agonist; and is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesic and alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options (e.g., non-opioid, non-barbiturate analgesics): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
資料來源：食藥署西藥許可證適應症（中文）、openFDA US SPL（英文，僅供對照）。
健保給付規定
上層 ATC 繼承條款
繼承自 ATC R05DA
§ 6.2.11 Caffeine citrate (如Peyona)：(115/1/1)
呼吸道藥物 › 其他
Caffeine citrate (如Peyona)：(115/1/1) 1.用於治療原發性早產兒呼吸暫停。 2.治療條件：受孕後週數(postmenstral age, PMA)未滿35週(35+0)早產兒，經臨床診斷具顯著呼吸暫停或心搏過緩情形。 3.停用時機(符合下列任一情形)： (1)受孕後週數(postmenstral age, PMA)33+0週以前，停用正壓呼吸器後，持續觀察5至7天，無臨床顯著呼吸暫停或心搏過緩發生，則停止用藥。 (2)受孕後週數(postmenstral age, PMA)33+0至35+0週，無臨床顯著呼吸暫停或心搏過緩發生，則停止用藥。
歷史演變（4 次異動）
| 生效日 | 異動說明 |
|---|---|
| 91/8/1 | legacy_boan_parsed:ch06.txt |
| 111/3/1 | legacy_boan_parsed:ch06.txt |
| 113/8/1 | legacy_boan_parsed:ch06.txt |
| 115/1/1 | legacy_boan_parsed:ch06.txt |
實證補充
本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。
台灣藥品與適應症：食藥署西藥許可證＋ATC＋外觀＋仿單開放資料 · FDA：openFDA US SPL · 健保給付：健保署「全民健康保險藥品給付規定」（更新日 2026-06-09）· 實證補充：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。